Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | CTSG | P08311 | 1/20 | 0.31 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.31 |
| ▸ | CMA1 | P23946 | 1/20 | 0.31 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9422673 | 0.96 | SMPD1 (0.37) | OPRM1SMPD1LMNACA2DNM1 | |
| SCHEMBL5108244 | 0.93 | CA2 (0.33) | CA2DNM1 | |
| SCHEMBL5101220 | 0.83 | — | — | |
| SCHEMBL7562904 | 0.78 | — | — | |
| SCHEMBL28309798 | 0.77 | SMPD1 (0.36) | OPRM1SMPD1LMNACA2DNM1 | |
| SCHEMBL9734928 | 0.77 | OPRM1 (0.37) | OPRM1SMPD1LMNA | |
| SCHEMBL28252014 | 0.76 | SMPD1 (0.47) | OPRM1SMPD1LMNACA2DNM1 | |
| SCHEMBL24627492 | 0.74 | SMPD1 (0.41) | OPRM1SMPD1LMNACA2DNM1 | |
| SCHEMBL24627696 | 0.74 | SMPD1 (0.41) | OPRM1SMPD1LMNACA2DNM1 | |
| SCHEMBL4495455 | 0.74 | SMPD1 (0.33) | OPRM1SMPD1LMNACA2DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101909-B2 | Compound of a ligand of 2-methoxy methylester-6-fluoronaphthalene, an aryl ligand and a linker; each ligand domain capable of binding to a Ca++ channel | THERAVANCE, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-7067620-B2 | Antibacterial agents | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | CUMBERLAND PHARMACEUTICALS INC. | 2005-08-04 | — | — | US | disclosed |
| US-6897305-B2 | Calcium channel drugs and uses | THERAVANCE, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040242561-A1 | Novel calcium channel drugs and uses | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-02-05 | — | — | US | disclosed |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-17 | — | — | US | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| US-6518242-B1 | Derivatives of glycopeptide antibacterial agents | THERAVANCE, INC. | 2003-02-11 | — | — | US | disclosed |
| US-6479498-B1 | COMPRISE 2-10 SODIUM CHANNEL LIGANDS COVALENTLY CONNECTED BY A LINKER OR LINKERS | THERAVANCE, INC. | 2002-11-12 | — | — | US | disclosed |
| WO-1999064050-A1 | NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064045-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063984-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999063992-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064052-A1 | NOVEL LEUKOTRIENE RECEPTOR ANTAGONISTS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064033-A1 | PHOSPHODIESTERASE-V MODULATOR DRUGS AND THEIR USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064044-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE 5-HT RECEPTORS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064040-A1 | NOVEL POLYENE MACROLIDE COMPOUNDS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999064037-A1 | NOVEL THERAPEUTIC AGENTS THAT MODULATE ENZYMATIC PROCESSES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171010-A1 | NOVEL ANTIBACTERIAL AGENTS | ENGASE, GALE, MGAM | OPRM1 2372/4885SMPD1 538/4885LMNA 4623/4885 |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | CACNB2, CACNA1B, CACNA1F | OPRM1 449/4885SMPD1 878/4885LMNA 3326/4885 |
| US-20040023290-A1 | Novel therapeutic agents that modulate enzymatic processes | RNASE1, ENGASE, ENTPD5 | OPRM1 4088/4885SMPD1 32/4885LMNA 4680/4885 |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | OPRM1 1099/4885SMPD1 1391/4885LMNA 4372/4885 |
| US-20040242561-A1 | Novel calcium channel drugs and uses | CACNB2, CACNA1B, CACNA1F | OPRM1 449/4885SMPD1 878/4885LMNA 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.